IDOGEN AB (PUBL)

IDOGEN AB (PUBL)

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, or the body's own cells or tissues in Sweden. Its advanced product candidate is IDO 8, designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII. The company also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection, primarily kidney transplant rejection; and IDO AID for severe and rare autoimmune diseases. The company was founded in 2008 and is headquartered in Lund, Sweden.

Idogen Ab (publ)_logo

Industry:
Company

Address:
Medicon Village, Lund, Sweden Zipcode 223 81

Country:
Sweden

Phone:
46 4 62 75 63 30

Market Cap:
63.85M
Total Revenue:
8.11M
Total Assets:
50.84M
Total Cash:
47.04M

CEOs: Lars Hedbys · Anders Karlsson

Website Url:
http://www.idogen.com


Key Executives
Name Title Pay Year Born
Mr. Anders Karlsson CEO & MD 997,733$ 1964(56 years old)
Mr. Ingvar Karlsson Chief Financial Officer N/A 1956(64 years old)
Mr. Dennis B. Henriksen M.Sc., Ph.D. Chief Technology Officer N/A 1962(58 years old)
Ms. Asa Schiott Chief Scientific Officer N/A N/A
Ms. Terese Hylander Project & Communications Mang. N/A N/A
Mr. Neil Thomas CBO & Patent Mang. N/A 1971(49 years old)
Ms. Christina Brattström Chief Medical Officer N/A N/A
Ms. Vicky Venizelos Chief Regulatory Officer N/A N/A



Financial & Stock
Company's stock symbol is IDOGEN.ST. Lastest price : 3.5000. Total volume :348.80k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.idogen.com

  • Host name: fudo.oderland.com
  • IP address: 91.201.60.21
  • Location: Sweden
  • Latitude: 59.3247
  • Longitude: 18.056
  • Timezone: Europe/Stockholm

Loading ...
Loading ...


More informations about "Idogen Ab (publ)" on Search Engine

Idogen – Engineering Immune Tolerance

Idogen.com Idogen’s tolerogenic cell therapy is developed to support patients with rare diseases with a high medical need. Our upcoming First in Human study in Hemophilia A patient with inhibitors is today highlighted in SvD. https://lnkd.in/eA39bxb 1 3 Twitter

Idogen AB (publ) announces rights issue of SEK 29 million

Idogen.com Jan 28, 2020 · The Board of Directors of Idogen AB (publ) (“Idogen” or the “Company”) has today, on January 28, 2020, subject to approval by the Extraordinary General Meeting, resolved to carry out a share issue of approximately SEK 29 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”).

Idogen AB (publ)

Idogen.com YEAR-END REPORT, JANUARY–DECEMBER 2018 3 Idogen AB (publ)│Corp. Reg. No.: 556756-8521 │ idogen.com SIGNIFICANT EVENTS DURING THE PERIOD • In January, the EU paid the first subpayment of the Horizon 2020 grant, an amount of MEUR 1.2. In December, a further MEUR 0.3 was paid. The remaining MEUR 1.4 will be paid out over the next 24 months.

IDOGEN AB (PUBL) : IDOGEN Stock Price | SE0014428561

Marketscreener.com IDOGEN AB (PUBL) (STO:IDOGEN) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share IDOGEN AB (PUBL) | NASDAQ STOCKHOLM AB: IDOGEN | NASDAQ STOCKHOLM AB

IDOGEN AB (PUBL) : Shareholders Board Members Managers and

Marketscreener.com Idogen AB is a Sweden-based company engaged in the healthcare industry. The Company is a research-driven entity developing a so called Tolerogenic Vaccine, a treatment concept for anti-drug antibodies, autoimmune diseases and transplant rejection.

Idogen : BioStock interview with Rolf Ljung, scientific

Marketscreener.com Idogen AB is preparing its most advanced project IDO8 for the first clinical trial in patients with severe hemophilia A. IDO 8 is a tolerogenic cell therapy with the intention to offer a new treatment to the most difficult patients, who develop antibodies against their required treatment with coagulation factor VIII.. In an interview with BioStock, Rolf Ljung, senior professor of pediatrics at ...

Idogen AB (publ) announces rights issue of SEK 29 million

News.cision.com idogen ab (publ) announces rights issue of sek 29 million tue, jan 28, 2020 17:50 cet. not for release, distribution or publication, directly or indirectly, in the united states of america, australia, canada, japan or any other jurisdiction in which the release, distribution or publication would be unlawful or require registration or any other measure.

Idogen : BioStock interview with Åsa Schiött, Chief

Marketscreener.com Apr 07, 2021 · Åsa Schiött has headed Idogen's research and development department in the role of Chief Scientific Officer since September 2020.. In an interview with BioStock, Åsa Schiött talks about her background, her first six months at Idogen and the exciting phase of preparing the company's tolerogenic cell therapy for the first clinical trial in patients with severe hemophilia A.

Idogen AB (publ) announces rights issue of SEK 29 million

Inderes.fi Idogen AB (publ) announces rights issue of SEK 29 million. The Board of Directors of Idogen AB (publ) ("Idogen" or the "Company") has today, on January 28, 2020, subject to approval by the Extraordinary General Meeting, resolved to carry out a share issue of approximately SEK 29 million with preferential rights for the Company's existing shareholders (the "Rights Issue").

Idogen AB (publ) Corp. Reg. No.

Idogen.com A A Y ‒ A 2019 Idogen AB (publ)│Corp. Reg. No.: 5556756-8521 │ idogen.com Idogen in brief Idogen (Spotlight Stock Market: IDOGEN) is a Swedish biotechnology company based in Lund. Idogen develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs

When Will Idogen AB (publ) (NGM:IDOGEN) Breakeven

Simplywall.st Idogen AB (publ)'s : Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, or the body’s own cells or tissues in Sweden. On 31 December 2019, the kr31m market-cap posted a loss of -kr32.7m for its most recent financial year.

Idogen AB (publ) Stock Forecast: down to 0.000001 SEK

Walletinvestor.com If you are looking for stocks with good return, Idogen AB (publ) stock can be a bad, high-risk 1-year investment option. Idogen AB (publ) real time quote is equal to 3.500 SEK at 2021-03-03, but your current investment may be devalued in the future. Get Our PREMIUM Forecast Now, from ONLY $7.49! - Try Now Risk-Free - Money-back guarantee!

IDOGEN AB (PUBL) : Stock Market News and Information

Marketscreener.com IDOGEN AB (PUBL) : News, information and stories for IDOGEN AB (PUBL) | Nasdaq Stockholm: | Nasdaq Stockholm

Idogen (OM:IDOGEN) - Share price, News & Analysis - Simply

Simplywall.st Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, or …

Idogen AB (publ) (IDOGEN.ST) - sg.finance.yahoo.com

Sg.finance.yahoo.com Find the latest Idogen AB (IDOGEN.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

Idogen - news.cision.com

News.cision.com Idogen AB (Spotlight Stock Market: IDOGEN) is a Swedish biotechnology company based in Lund. Idogen develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues. Idogen’s intention is to revolutionize the treatment of several disorders in which the body’s immune system does not ...

Idogen AB (publ) (IDOGEN.ST) - Yahoo

Finance.yahoo.com Find the latest Idogen AB (IDOGEN.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Idogen AB (publ) (IDOGEN.ST) Stockholm ...

Offerings - Arctic Securities Sweden

Arctic.com Apr 12, 2021 · ExpreS2ion Biotech Holding AB (publ) is referred to as “ExpreS2ion” or “the Company”. Three (3) warrant of series TO4 entitles the holder to subscribe for one (1) new share in ExpreS2ion at a subscription price of SEK 22.00 during the period from April 12 – April 26, 2021.

Introducing Idogen (NGM:IDOGEN), The Stock That Tanked 93%

Simplywall.st Dec 21, 2019 · Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So take a moment to sympathize with the long term shareholders of Idogen AB (publ) (), who have seen the share price tank a massive 93% over a three year period.That would be a disturbing experience.

Idogen determines record date for consolidation of shares

News.cision.com Idogen determines record date for consolidation of shares Wed, May 20, 2020 11:12 CET. The Board of Directors of Idogen AB (”Idogen” or the ”Company”) has resolved that the record date for the consolidation of shares, that was resolved on the Annual General Meeting on …

Inbjudan till teckning av units i Idogen AB (publ)

Res.cloudinary.com Idogen AB (publ) Observera att detta endast utgör ett kort utdrag ur prospektet och att varje beslut att investera i Idogen ska baseras på en bedömning av prospektet i sin helhet. Prospektet finns tillgängligt på www.idogen.com. Frågor om teckning och betalning besvaras av emissionsinstitutet Aqurat Fondkommission AB (www.aqurat.se).

Idogen AB, IDOGEN:STO summary - FT.com

Markets.ft.com Idogen AB is a Sweden-based company engaged in the healthcare industry. The Company is a research-driven entity developing a so called Tolerogenic Vaccine, a treatment concept for anti-drug antibodies, autoimmune diseases and transplant rejection. Its treatment is based on the patient's own dendritic cells (a type of white blood cell) and is taken out and reprogrammed in vitro and then given ...

Nomination Committee nominates cell therapy expert to

News.cision.com Ahead of the Idogen AB (publ) Annual General Meeting on 12 May 2020, the Nomination Committee has presented its proposal regarding the election of and payment of fees to the Board of Directors and auditor. The Nomination Committee proposes the re-election of Agneta Edberg, Leif Salford and Christina Herder, and the election of Sharon Longhurst ...

Investor Relations :: Inogen, Inc. (INGN)

Investor.inogen.com Apr 7, 2021. Inogen Announces Appointment of Chief Commercial Officer, Transition of Certain Officers, and Preliminary, Unaudited First Quarter 2021 Revenue Range

News | NextCell Pharma AB

Nextcellpharma.com Discussions between the boards of NextCell Pharma AB (publ) ("NextCell") and Idogen AB (publ) ("Idogen") (together "The companies") regarding a possible merger, are still ongoing. Further information will be published no later than the opening of trading on Wednesday, 08 May 2019.

Idogen AB, NGM:IDOGEN | Stock Price, Short Interest

Ortex.com Idogen AB, IDOGEN: Overview with real-time Short Interest, Analysts Estimates, Insiders, Director Dealings, Valuation, EPS, DPS, News, Peers, Events, Short Interests ...

Informationsbroschyr

Ir.spotlightstockmarket.com Idogen AB Företrädesemission 22 Annons Idogen i korthet Kort om Idogen Idogen är ett svenskt bioteknikbolag baserat i Lund. Idogen ut-vecklar tolerogena cellterapier med syfte att motverka att bio-logiska läkemedel, transplanterade organ eller kroppens egna celler eller vävnader angrips av patientens immunförsvar. Be-

Did Changing Sentiment Drive Idogen's (NGM:IDOGEN) Share

Simplywall.st As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So spare a thought for the long term shareholders of Idogen AB (publ) (); the share price is down a whopping 94% in the last three years.That would be a disturbing experience.

Idogen AB | LinkedIn

Linkedin.com Idogen develops tolerogenic cell therapies which re-program the immune system. The term "tolerogenic" refers to that the immune system will tolerate the selected molecule after treatment.

Transactions - Arctic Securities Sweden

Arctic.com Idogen AB (publ) Idogen is a Swedish biotech company that develops tolerogenic cell therapies with the aim of preventing attacks from the body's immune system. Issuer

IDOGEN | Idogen AB Stock Price & News - WSJ

Wsj.com View the latest Idogen AB (IDOGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Bulletin from the annual general meeting in Idogen AB on

News.cision.com Idogen AB (publ) For more information, please contact: Anders Karlsson, CEO, Idogen AB Tel: +46 (0) 70 918 00 10 E-mail: [email protected] . This information was submitted for publication, through the agency of the contact person set out above, on May 12, 2020.

Årsredovisning

Ir.spotlightstockmarket.com Årsredovisning 2017 Idogen AB (publ) Org.nr 556756-8521 www.idogen.com

Nasdaq Stockholm Welcomes Idogen to Nasdaq First North

Newsclient.omxgroup.com Jun 04, 2020 · Nasdaq Stockholm Welcomes Idogen to Nasdaq First North Growth Market. Stockholm, June 4, 2020 – Nasdaq (Nasdaq: NDAQ) announces that trading in Idogen AB shares (short name: IDOGEN) commence today on Nasdaq First North Premier Growth Market in Stockholm.The company belongs to the Health care sector. Idogen is the 19th company to be admitted to trading on Nasdaq’s …

Idogen on Twitter: "Idogen AB (”Idogen”) har idag

Twitter.com Apr 08, 2021

AroCell - Precision monitoring in cancer care - Arocell TK

Arocell.com AroCell AB is a Swedish in vitro diagnostics company focusing on the precision monitoring of patients suffering from hematological malignancies, breast cancer, and other solid tumors. We are developing, manufacturing and selling products for the measurement of human Thymidine Kinase 1 (TK1) concentration in blood.

Ingvar Karlsson - CFO - Idogen AB | LinkedIn

Se.linkedin.com Idogen is public… Idogen AB develops a unique treatment concept for inducing immune tolerance. The method is based on autologous cell therapy of the patient’s own dendritic cells and pharmacological upregulation of the endogenous enzyme IDO-1 with substance zebularine in these cells.

IDOGEN AB Share Price - IDOGEN Share Price

Stockopedia.com Shares in Idogen AB are currently trading at SEK3.12 and the price has moved by -56.44% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Idogen AB price has moved by -55.03% over the past year.

SWIPP — SWIPP

Swipp.se AcuCort AB (publ), Idogen AB (publ), Lipopeptide AB (Stockholm), and VP Business Development of Camurus AB (publ). He has also had numerous consultancy assignment for other public or private companies. He received his M.Sc. and his Ph.D. at the Faculty of Engineering at Lund University, where he is also Associate Professor since 1999.

Double Bond Pharmaceutical International AB (publ), DBP B

Markets.ft.com Idogen AB; Toleranzia AB; Hemcheck Sweden AB; Promore Pharma AB; Asarina Pharma AB (publ) IDL Biotech AB; Odi Pharma AB (publ) Veg of Lund AB (publ) Save Clear. Go to Interactive chart. Key statistics. On Thursday, Double Bond Pharmaceutical International AB (publ) (DBP B:AKT) closed at 2.00, 58.48% above the 52 week low of 1.26 set on Mar 12 ...

Ingvar Karlsson - Elicera Therapeutics AB

Elicera.com Ingvar has worked as his own consultant since 2014 and is currently a part-time CFO at Idogen AB (publ) where he continues. At Idogen, he has recently carried out issues and led the work of moving from Spotlight to listing on the First North Growth Market of Idogen's share.

Inbjudan till teckning av units - Cloudinary

Res.cloudinary.com Idogen AB (publ) med organisationsnummer 556756-8521. Handelsbeteckningen är IDOGEN. B.2 Säte och bolagsform Bolagets styrelse har sitt säte i Lunds kommun. Bolaget är ett svenskt publikt aktiebolag bildat i Sverige enligt svensk rätt och bedriver sin verksamhet enligt svensk rätt. Bolagets associationsform regleras av aktiebolagslagen ...

Design and Art Direction - Jens Martin Design

Jensmartin.com Idogen is a listed Swedish biotechnology company based in Lund. Idogen develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues.

IDOGEN:FN Stockholm Stock Quote - Idogen AB - Bloomberg

Bloomberg.com Stock analysis for Idogen AB (IDOGEN:FN Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

News | Elicera Therapeutics AB

Elicera.com Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Org.nr: 556966-4955. Elicera Therapeutics AB (publ) World Trade Center Göteborg Mässans gata 10, floor 7 …

Nyheter | Elicera Therapeutics AB

Elicera.com Ingvar har arbetat som egen konsult sedan 2014 och är idag deltids CFO på cellterapibolaget Idogen AB (publ) där han fortsätter. På Idogen har han nyligen genomfört emissioner och lett arbetet med flytten från Spotlight till notering på First North Growth Market av Idogens aktie.

Investing Ideas - Swedish Pharmaceuticals & Biotech

Simplywall.st Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, or …

P/E Ratio For Probi AB (publ) (PROB) | finbox.com

Finbox.com The following section summarizes insights on Probi AB (publ)'s P/E Ratio: Dec 2012 Dec 2014 Dec 2016 Dec 2018 Dec 2020 20.0x 40.0x 60.0x 80.0x Performance Summary